Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment

Chidamide plus Prednisone, Etoposide, and Thalidomide for Untreated Angioimmunoblastic T‐cell Lymphoma in a Chinese Population: A Multicenter Phase II Trial

(2022) Yawen Wang et al.   AMERICAN JOURNAL OF HEMATOLOGY

Chidamide with PEL Regimen (Prednisone, Etoposide, Lenalidomide) for Elderly or Frail Patients with Relapsed/Refractory Diffuse Large B‐Cell Lymphoma ‐Results of a Single Center ,Retrospective Cohort in China

(2022) Yawen Wang et al.   HEMATOLOGICAL ONCOLOGY

CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor

(2022) Jia-Shiong Chen et al.   Scientific Reports

Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma

(2022) Jinni Wang et al.   Frontiers in Immunology

Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma

(2021) Yi Que et al.   Journal for ImmunoTherapy of Cancer

Chidamide Combined With Doxorubicin Induced p53-Driven Cell Cycle Arrest and Cell Apoptosis Reverse Multidrug Resistance of Breast Cancer

(2021) Lixia Cao et al.   Frontiers in Oncology

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

(2021) Kun Tu et al.   ACS Applied Materials & Interfaces

The epigenetic immunomodulator, HBI-8000, enhances the response and reverses resistance to checkpoint inhibitors

(2021) Reid P. Bissonnette et al.   BMC CANCER

A new conditioning regimen with chidamide, cladribine, gemcitabine and busulfan significantly improve the outcome of high‐risk or relapsed/refractory non‐Hodgkin 's lymphomas

(2021) Jie Ji et al.   INTERNATIONAL JOURNAL OF CANCER

Safety and efficacy of chidamide in combination with decitabine plus anti-PD-1 camrelizumab after relapse or progression on decitabine-plus-camrelizumab in classical Hodgkin lymphoma.

(2021) Chunmeng Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

The Synergistic Anti-Tumor Activity of EZH2 Inhibitor SHR2554 and HDAC Inhibitor Chidamide through ORC1 Reduction of DNA Replication Process in Diffuse Large B Cell Lymphoma

(2021) Xing Wang et al.   Cancers

Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas

(2021) Xu Huang et al.   Journal of Oncology

A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL

(2021) Chong Wei et al.   Frontiers in Oncology

A Phase II Trial of the Double Epigenetic Priming Regimen Including Chidamide and Decitabine for Relapsed/Refractory Acute Myeloid Leukemia

(2021) Jia Yin et al.   Frontiers in Oncology

Epigenetic Therapy Promotes the Ratio of Th1/Th17 Lineage to Reverse Immune Evasion and Treat Leukemia Relapse Post-allogeneic Stem Cell Transplantation in Non-APL AML Patients

(2021) Yang Xi et al.   Frontiers in Molecular Biosciences

Novel Induction Therapy for Newly Diagnosed Extranodal Natural Killer/T Cell Lymphoma (ENKTL) Treated By Anti-PD-1 Antibody Plus Histone Deacetylase Inhibitor Followed By P-GemOx Regimen

(2021) Gao Yan et al.   BLOOD

CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma

(2021) Yichen Sun et al.   CANCER LETTERS

Epigenetic modulation of antitumor immunity for improved cancer immunotherapy

(2021) Enyong Dai et al.   Molecular Cancer

Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma

(2021) Kai Xue et al.   Cell Death & Disease

Upregulation of CD22 by Chidamide promotes CAR T cells functionality

(2021) Xin Yang et al.   Scientific Reports

A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China

(2021) Weiping Liu et al.   Frontiers in Oncology

Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer

(2021) Yanchun Meng et al.   Annals of Palliative Medicine

Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20

(2020) Xu-Wen Guan et al.   Cell Death & Disease

Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

(2020) Patrizia Mondello et al.   Cancer Discovery

Soft-tissue sarcoma in adults: An update on the current state of histiotype-specific management in an era of personalized medicine

(2020) Adriana C. Gamboa et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

(2020) Estefanía García-Guerrero et al.   LEUKEMIA

Chidamide epigenetically represses autophagy and exerts cooperative antimyeloma activity with bortezomib

(2020) Li Xu et al.   Cell Death & Disease

Clinicopathological Characteristics and Mutational Profiling of Adult T-Cell Lymphoblastic Lymphoma in a Chinese Population

(2020) Feili Chen et al.   Cancer Management and Research

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy

(2020) Yang Gao et al.   NATURE CELL BIOLOGY

Preclinical evaluation of a regimen combining chidamide and ABT-199 in acute myeloid leukemia

(2020) Kai Chen et al.   Cell Death & Disease

Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma

(2020) Mu-Chen Zhang et al.   Clinical Epigenetics

Chidamide, decitabine, cytarabine, aclarubicin, and granulocyte colony-stimulating factor (CDCAG) in patients with relapsed/refractory acute myeloid leukemia: a single-arm, phase 1/2 study

(2020) Lixin Wang et al.   Clinical Epigenetics

High Expression of Succinate Dehydrogenase Subunit A Which Is Regulated by Histone Acetylation, Acts as a Good Prognostic Factor of Multiple Myeloma Patients

(2020) Yifeng Sun et al.   Frontiers in Oncology

The histone deacetylase inhibitor chidamide induces intermittent viraemia in HIV‐infected patients on suppressive antiretroviral therapy

(2020) JH Li et al.   HIV MEDICINE

Emerging epigenetic-modulating therapies in lymphoma

(2019) David Sermer et al.   Nature Reviews Clinical Oncology

Breast Cancer Treatment

(2019) Adrienne G. Waks et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers

(2019) Hideaki Ogiwara et al.   CANCER CELL

Yet another susceptibility variant for ALL: what’s next?

(2019) Kjeld Schmiegelow   BLOOD

Addition of Low-Dose Decitabine to Anti–PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma

(2019) Jing Nie et al.   JOURNAL OF CLINICAL ONCOLOGY

Circulating PD‐1 (+) cells may participate in immune evasion in peripheral T‐cell lymphoma and chidamide enhance antitumor activity of PD‐1 (+) cells

(2019) Wei Zhang et al.   Cancer Medicine

Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Zefei Jiang et al.   LANCET ONCOLOGY

Advances in epigenetics link genetics to the environment and disease

(2019) Giacomo Cavalli et al.   NATURE

Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

(2019) Peng-Peng Xu et al.   Lancet Haematology

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

(2019) Ken Kato et al.   LANCET ONCOLOGY

Chidamide Enhances the Cytotoxicity of Cytarabine and Sorafenib in Acute Myeloid Leukemia Cells by Modulating H3K9me3 and Autophagy Levels

(2019) He Huang et al.   Frontiers in Oncology

Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells

(2018) Sheng Yang et al.   BIOMEDICINE & PHARMACOTHERAPY

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

(2018) Meng-Meng Ji et al.   HAEMATOLOGICA

Expression of PD-1 on peripheral blood Treg cells is related to the diagnosis, prognosis and treatment of T cell non-Hodgkin lymphoma

(2018) Mengxuan Zuo et al.   LEUKEMIA RESEARCH

Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified

(2018) Meng-Meng Ji et al.   HAEMATOLOGICA

Epigenetic tools (The Writers, The Readers and The Erasers) and their implications in cancer therapy

(2018) Subhankar Biswas et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Low-dose chidamide restores immune tolerance in ITP patients and mice by modulating nTreg cells and CTLA4 expression

(2018) Hong-yu Zhao et al.   BLOOD

Entinostat: a promising treatment option for patients with advanced breast cancer

(2017) Roisin M Connolly et al.   Future Oncology

Modulation of antitumor immunity with histone deacetylase inhibitors

(2017) Tyler R McCaw et al.   Immunotherapy

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

(2017) Yuankai Shi et al.   Journal of Hematology & Oncology

Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma

(2017) Huilai Zhang et al.   LEUKEMIA RESEARCH

Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4

(2017) Tao Jiang et al.   Oncotarget

Sirtuin-1 Activation Controls Tumor Growth by Impeding Th17 Differentiation via STAT3 Deacetylation

(2017) Emeric Limagne et al.   Cell Reports

Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells

(2017) Yin Li et al.   Clinical Epigenetics

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

A phase I trial of an oral subtype-selective histone deacetylase inhibitor, chidamide, in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer

(2016) Xingsheng Hu et al.   Chinese Journal of Cancer Research

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Chidamide Inhibits Aerobic Metabolism to Induce Pancreatic Cancer Cell Growth Arrest by Promoting Mcl-1 Degradation

(2016) Mu He et al.   PLoS One

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

(2015) Y. Shi et al.   ANNALS OF ONCOLOGY

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

(2015) Madhusoodanan Mottamal et al.   MOLECULES

Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression

(2015) H. Ogiwara et al.   Cancer Discovery

Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells

(2014) You Zhou et al.   BIOMEDICINE & PHARMACOTHERAPY

Overexpression of histone deacetylases in cancer cells is controlled by interplay of transcription factors and epigenetic modulators

(2014) Hui Yang et al.   FASEB JOURNAL

CD4+ T cell lineage integrity is controlled by the histone deacetylases HDAC1 and HDAC2

(2014) Nicole Boucheron et al.   NATURE IMMUNOLOGY

Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer

(2014) BIN ZHAO et al.   ONCOLOGY REPORTS

Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment

(2014) De-Si Pan et al.   MedChemComm

Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells

(2013) Zhixin Qiao et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma

(2013) Patrick J. Stiff et al.   NEW ENGLAND JOURNAL OF MEDICINE

CS055 (Chidamide/HBI-8000), a novel histone deacetylase inhibitor, induces G1arrest, ROS-dependent apoptosis and differentiation in human leukaemia cells

(2012) Ke Gong et al.   BIOCHEMICAL JOURNAL

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

(2012) Mei Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity

(2011) Zhi-Qiang Ning et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Regulation of chromatin by histone modifications

(2011) Andrew J Bannister et al.   CELL RESEARCH

Inactivating mutations of acetyltransferase genes in B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE

A novel histone deacetylase inhibitor Chidamide induces apoptosis of human colon cancer cells

(2010) Lin Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

(2008) Michael Pfreundschuh et al.   LANCET ONCOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE